{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:44:08Z","timestamp":1790462648523,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","award":["1639\/MOB\/V\/2017\/0"],"award-info":[{"award-number":["1639\/MOB\/V\/2017\/0"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005982","name":"Politechnika Wroc\u0142awska","doi-asserted-by":"publisher","award":["82013902"],"award-info":[{"award-number":["82013902"]}],"id":[{"id":"10.13039\/501100005982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An efficient treatment against a COVID-19 disease, caused by the novel coronavirus SARS-CoV-2 (CoV2), remains a challenge. The papain-like protease (PL\n                    <jats:sup>pro<\/jats:sup>\n                    ) from the human coronavirus is a protease that plays a critical role in virus replication. Moreover, CoV2 uses this enzyme to modulate the host\u2019s immune system to its own benefit. Therefore, it represents a highly promising target for the development of antiviral drugs. We used Approximate Bayesian Computation tools, molecular modelling and enzyme activity studies to identify highly active inhibitors of the PL\n                    <jats:sup>pro<\/jats:sup>\n                    . We discovered organoselenium compounds, ebselen and its structural analogues, as a novel approach for inhibiting the activity of PL\n                    <jats:sup>pro<\/jats:sup>\n                    CoV2. Furthermore, we identified, for the first time, inhibitors of PL\n                    <jats:sup>pro<\/jats:sup>\n                    CoV2 showing potency in the nanomolar range. Moreover, we found a difference between PL\n                    <jats:sup>pro<\/jats:sup>\n                    from SARS and CoV2 that can be correlated with the diverse dynamics of their replication, and, putatively to disease progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-83229-6","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T06:03:58Z","timestamp":1613023438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2"],"prefix":"10.1038","volume":"11","author":[{"given":"Ewelina","family":"Weglarz-Tomczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub M.","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Talma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Burda-Grabowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Giurg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Brul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"83229_CR1","unstructured":"Summary Table of SARS Cases by Country, 1 November 2002\u20137 August 2003. WHO: Geneva (August 15, 2003). http:\/\/www.who.int\/csr\/sars\/country\/2003_08_15\/en\/."},{"key":"83229_CR2","doi-asserted-by":"publisher","first-page":"7790","DOI":"10.1128\/JVI.01244-13","volume":"87","author":"RJ de Groot","year":"2013","unstructured":"de Groot, R. J. et al. Middle east respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group. J. Virol. 87, 7790\u20137792 (2013).","journal-title":"J. Virol."},{"key":"83229_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"83229_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"83229_CR5","unstructured":"WHO Novel Coronavirus (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. (Data obtained on October 21, 2020)."},{"key":"83229_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/187152609787847659","volume":"9","author":"TR Tong","year":"2009","unstructured":"Tong, T. R. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect. Disord. Drug Targets 9, 223\u2013245 (2009).","journal-title":"Infect. Disord. Drug Targets"},{"key":"83229_CR7","first-page":"20","volume":"52","author":"M Prajapat","year":"2020","unstructured":"Prajapat, M. et al. Drug targets for corona virus: A systematic review. Indian J. Pharmacol. 52, 20 (2020).","journal-title":"Indian J. Pharmacol."},{"key":"83229_CR8","first-page":"e29","volume":"8","author":"A Rismanbaf","year":"2020","unstructured":"Rismanbaf, A. Potential treatments for COVID-19; a narrative literature review. Arch. Acad. Emerg. Med. 8, e29 (2020).","journal-title":"Arch. Acad. Emerg. Med."},{"key":"83229_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.008","author":"C Wu","year":"2020","unstructured":"Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. https:\/\/doi.org\/10.1016\/j.apsb.2020.02.008 (2020) ((in Press)).","journal-title":"Acta Pharm. Sin. B."},{"key":"83229_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"M B\u00e1ez-Santos","year":"2015","unstructured":"B\u00e1ez-Santos, M., St. John, S. E. & Mesecar, A. D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21\u201338 (2015).","journal-title":"Antiviral Res."},{"key":"83229_CR11","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","volume":"78","author":"BH Harcourt","year":"2004","unstructured":"Harcourt, B. H. et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol. 78, 13600\u201313612 (2004).","journal-title":"J. Virol."},{"key":"83229_CR12","doi-asserted-by":"publisher","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"S Ullrich","year":"2020","unstructured":"Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 30, 127377 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"83229_CR13","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1021\/bi0504761","volume":"44","author":"YS Han","year":"2005","unstructured":"Han, Y. S. et al. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): Expression, purification, characterization, and inhibition. Biochemistry 44, 10349\u201310359 (2005).","journal-title":"Biochemistry"},{"key":"83229_CR14","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","volume":"79","author":"HA Lindner","year":"2005","unstructured":"Lindner, H. A. et al. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J. Virol. 79, 15199\u201315208 (2005).","journal-title":"J. Virol."},{"key":"83229_CR15","doi-asserted-by":"publisher","first-page":"32208","DOI":"10.1074\/jbc.M704870200","volume":"282","author":"SG Devaraj","year":"2007","unstructured":"Devaraj, S. G. et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282, 32208\u201332221 (2007).","journal-title":"J. Biol. Chem."},{"key":"83229_CR16","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","volume":"79","author":"N Barretto","year":"2005","unstructured":"Barretto, N. et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 79, 15189\u201315198 (2005).","journal-title":"J. Virol."},{"key":"83229_CR17","doi-asserted-by":"publisher","first-page":"e1004113","DOI":"10.1371\/journal.ppat.1004113","volume":"10","author":"K Ratia","year":"2014","unstructured":"Ratia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C. & Mesecar, A. D. Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 10, e1004113 (2014).","journal-title":"PLoS Pathog."},{"key":"83229_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.abb.2007.07.006","volume":"466","author":"HA Lindner","year":"2007","unstructured":"Lindner, H. A. et al. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch. Biochem. Biophys. 466, 8\u201314 (2007).","journal-title":"Arch. Biochem. Biophys."},{"key":"83229_CR19","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-27134\/v1","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Inhibition of papain-like protease PLpro blocks SARS-CoV-2 spread and promotes anti-viral immunity. Nature https:\/\/doi.org\/10.21203\/rs.3.rs-27134\/v1 (2020) ((under review)).","journal-title":"Nature"},{"key":"83229_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.29.068890","author":"W Rut","year":"2020","unstructured":"Rut, W. et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv https:\/\/doi.org\/10.1101\/2020.04.29.068890 (2020) ((preprint)).","journal-title":"bioRxiv"},{"key":"83229_CR21","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","volume":"41","author":"GK Azad","year":"2014","unstructured":"Azad, G. K. & Tomar, R. S. Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways. Mol. Biol. Rep. 41, 4865\u20134879 (2014).","journal-title":"Mol. Biol. Rep."},{"key":"83229_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-0826-3","volume":"3","author":"V Chantadul","year":"2020","unstructured":"Chantadul, V. et al. Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy. Commun. Biol. 3, 1\u201310. https:\/\/doi.org\/10.1038\/s42003-020-0826-3 (2020).","journal-title":"Commun. Biol."},{"key":"83229_CR23","doi-asserted-by":"publisher","first-page":"18418","DOI":"10.18632\/oncotarget.4099","volume":"6","author":"PD Hanavan","year":"2015","unstructured":"Hanavan, P. D. et al. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget 6, 18418\u201318428 (2015).","journal-title":"Oncotarget"},{"key":"83229_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.24820\/ark.5550190.p009.797","volume":"(part ii)","author":"M Pietka-Ottlik","year":"2017","unstructured":"Pietka-Ottlik, M. et al. Synthesis of new alkylated and methoxylated analogues of ebselen with antiviral and antimicrobial properties. Arkivoc (part ii), 546\u2013556 (2017).","journal-title":"Arkivoc"},{"key":"83229_CR25","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/cb500512z","volume":"9","author":"S Mukherjee","year":"2014","unstructured":"Mukherjee, S. et al. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem. Biol. 9, 2393\u20132403 (2014).","journal-title":"ACS Chem. Biol."},{"key":"83229_CR26","doi-asserted-by":"publisher","first-page":"8207","DOI":"10.1093\/nar\/17.20.8207","volume":"17","author":"K Moriet","year":"1989","unstructured":"Moriet, K. & al. ,. Phosphoroselenoate oligodeoxynucleotides: Synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity. Nucleic Acids Res. 17, 8207\u20138219 (1989).","journal-title":"Nucleic Acids Res."},{"key":"83229_CR27","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1021\/ol1005906","volume":"12","author":"V Alexander","year":"2010","unstructured":"Alexander, V. et al. A new DNA building block, 4\u2032-selenothymidine: Synthesis and modification to 4\u2032-seleno-AZT as a potential anti-HIV agent. Org. Lett. 12, 2242\u20132245 (2010).","journal-title":"Org. Lett."},{"key":"83229_CR28","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1021\/acs.jmedchem.5b01183","volume":"58","author":"L Sancineto","year":"2015","unstructured":"Sancineto, L. et al. Design and synthesis of diselenobisbenzamides (DISeBAs) as nucleocapsid protein 7 (NCp7) inhibitors with anti-HIV activity. J. Med. Chem. 58, 9601\u20139614 (2015).","journal-title":"J. Med. Chem."},{"key":"83229_CR29","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.3390\/molecules15118214","volume":"15","author":"M Pietka-Ottlik","year":"2010","unstructured":"Pietka-Ottlik, M., Potaczek, P., Piasecki, E. & Mlochowski, J. Crucial role of selenium in the virucidal activity of benzisoselenazol-3 (2H)-ones and related diselenides. Molecules 15, 8214\u20138228 (2010).","journal-title":"Molecules"},{"key":"83229_CR30","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3390\/molecules13112740","volume":"13","author":"M Al-Smadi","year":"2008","unstructured":"Al-Smadi, M. & Al-Momani, F. Synthesis, characterization and antimicrobial activity of new 1, 2, 3-selenadiazoles. Molecules 13, 2740\u20132749 (2008).","journal-title":"Molecules"},{"key":"83229_CR31","doi-asserted-by":"publisher","first-page":"100005","DOI":"10.1016\/j.xcrm.2020.100005","volume":"1","author":"M Garland","year":"2020","unstructured":"Garland, M. et al. The clinical drug ebselen attenuates inflammation and promotes microbiome recovery in mice after antibiotic treatment for CDI. Cell Rep. Med. 1, 100005. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100005 (2020).","journal-title":"Cell Rep. Med."},{"key":"83229_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jpsychires.2018.11.021","volume":"109","author":"F Martini","year":"2019","unstructured":"Martini, F. et al. A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer\u2019s disease. J. Psychiatr. Res. 109, 107\u2013117 (2019).","journal-title":"J. Psychiatr. Res."},{"key":"83229_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1006\/abbi.1997.0334","volume":"348","author":"R Gopalakrishna","year":"1997","unstructured":"Gopalakrishna, R., Gundimeda, U. & Chen, Z. H. Cancer-preventive selenocompounds induce a specific redox modification of cysteine-rich regions in Ca(2+)-dependent isoenzymes of protein kinase. Arch. Biochem. Biophys. 348, 25\u201336 (1997).","journal-title":"Arch. Biochem. Biophys."},{"key":"83229_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fob.2014.01.002","volume":"4","author":"GK Azad","year":"2014","unstructured":"Azad, G. K. et al. Ebselen induces reactive oxygen species (ROS)-mediated cytotoxicity in Saccharomyces cerevisiae with inhibition of glutamate dehydrogenase being a target. FEBS Open Bio. 4, 77\u201389 (2014).","journal-title":"FEBS Open Bio."},{"key":"83229_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2223-y","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature https:\/\/doi.org\/10.1038\/s41586-020-2223-y (2020).","journal-title":"Nature"},{"key":"83229_CR36","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM B\u00e1ez-Santos","year":"2014","unstructured":"B\u00e1ez-Santos, Y. M. et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. Med. Chem. 57, 2393\u20132412 (2014).","journal-title":"Med. Chem."},{"key":"83229_CR37","doi-asserted-by":"publisher","unstructured":"Osipiuk, J. et al. The crystal structure of papain-like protease of SARS CoV-2. https:\/\/doi.org\/10.2210\/pdb6W9C\/pdb.","DOI":"10.2210\/pdb6W9C\/pdb"},{"key":"83229_CR38","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/1873-3468.13531","volume":"593","author":"JM Tomczak","year":"2019","unstructured":"Tomczak, J. M. & W\u0119glarz-Tomczak, E. Estimating kinetic constants in the Michaelis\u2013Menten model from one enzymatic assay using Approximate Bayesian Computation. FEBS Lett. 593, 2742\u20132750 (2019).","journal-title":"FEBS Lett."},{"key":"83229_CR39","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1016\/j.bmcl.2016.09.050","volume":"26","author":"E Weglarz-Tomczak","year":"2016","unstructured":"Weglarz-Tomczak, E. et al. Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives\/analoques: Synthesis, inhibitory activity and molecular modeling study. Bioorg. Med. Chem. Lett. 26, 5254\u20135259 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"83229_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.biochi.2012.10.018","volume":"95","author":"E Weglarz-Tomczak","year":"2013","unstructured":"Weglarz-Tomczak, E. et al. An integrated approach to the ligand binding specificity of Neisseria meningitidis M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modelling. Biochimie 95, 419\u2013428 (2013).","journal-title":"Biochimie"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83229-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T22:33:13Z","timestamp":1670020393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83229"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83229-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3640"}}